Werbung
Werbung

RGNX

RGNX logo

REGENXBIO Inc.

14.57
USD
Gesponsert
-0.43
-2.85%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

15.02

+0.44
+3.04%

RGNX Ergebnisberichte

Positives Überraschungsverhältnis

RGNX übertreffen die 16 der letzten 40Schätzungen.

40%

Nächster Bericht

Datum des nächsten Berichts
11. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$50.48M
/
-$0.85
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+69.79%
/
-29.17%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+137.97%
/
-15.84%

REGENXBIO Inc. earnings per share and revenue

On 06. Nov. 2025, RGNX reported earnings of -1.20 USD per share (EPS) for Q3 25, beating the estimate of -1.33 USD, resulting in a 9.88% surprise. Revenue reached 29.73 million, compared to an expected 24.61 million, with a 20.83% difference. The market reacted with a -3.79% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.85 USD, with revenue projected to reach 50.48 million USD, implying an decrease of -29.17% EPS, and increase of 69.79% in Revenue from the last quarter.
FAQ
For Q3 2025, REGENXBIO Inc. reported EPS of -$1.20, beating estimates by 9.88%, and revenue of $29.73M, 20.83% above expectations.
The stock price moved down -3.79%, changed from $11.61 before the earnings release to $11.17 the day after.
The next earning report is scheduled for 11. März 2026.
Based on 14 analysts, REGENXBIO Inc. is expected to report EPS of -$0.85 and revenue of $50.48M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung